DDInter1837 DDInter927
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Toremifene {u} (Compound) resembles {v} (Compound) Doxylamine
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
Toremifene {u} (Compound) upregulates {v} (Gene) SQSTM1
Toremifene {u} (Compound) downregulates {v} (Gene) PMM2
Toremifene {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Toremifene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metolazone
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Toremifene (Compound) resembles Doxylamine (Compound)
Toremifene (Compound) treats breast cancer (Disease)
Toremifene (Compound) binds ABCB1 (Gene)
Toremifene (Compound) upregulates SQSTM1 (Gene)
Toremifene (Compound) downregulates PMM2 (Gene)
Toremifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Toremifene may lead to a major life threatening interaction when taken with Pazopanib